MB
CRVS icon

MPM BioImpact’s Corvus Pharmaceuticals CRVS Stock Holding History

MPM BioImpact’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.5M Sell
1,674,875
-1,068,796
-39% -$17.1M 1.89% 23
2025
Q4 		$21.1M Buy
+2,743,671
New +$21.6M 2.42% 19

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MPM BioImpact's CRVS Position: Q1 2026 in Review

MPM BioImpact reduced its Corvus Pharmaceuticals (CRVS) stake by 39% in Q1 2026, selling an estimated $17.1M and leaving 1,674,875 shares worth $24.5M. The position accounts for 1.89% of the portfolio, ranked #23.

MPM BioImpact first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • MPM BioImpact held 1,674,875 shares of Corvus Pharmaceuticals worth $24.5M as of Q1 2026.
  • MPM BioImpact sold 1,068,796 Corvus Pharmaceuticals shares in Q1 2026, an estimated $17.1M.
  • Corvus Pharmaceuticals made up 1.89% of MPM BioImpact's portfolio in Q1 2026, its #23 holding.
  • MPM BioImpact first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.